The two new centres look to explore lung magnetic resonance imaging for cystic fibrosis (CF) and the pharmacological repair of bicarbonate transport in CF
This study is aiming to learn more about the safety and tolerability of the combination modulator treatment made up of Elexacaftor (ELX), Tezacaftor (TEZ) and Ivacaftor (IVA) (also known by its brand name Kaftrio) in children aged 12 to less than 24 months. This treatment is already approved for use in the UK for certain groups of people with CF, but has not yet been approved for this age group. There will be two parts to the study: Part A and Part B. Children taking part in Part A will receive ELX/TEZ/IVA in the morning and IVA in the evening...
